================================================================================

                                  UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                               -------------------


                                    FORM 10-Q

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

                   For the Fiscal Quarter Ended June 30, 2000

[ ]  TRANSITION  REPORT  PURSUANT  TO  SECTION  13 OR  15(d)  OF THE  SECURITIES
     EXCHANGE ACT OF 1934

               For the Transition period from _____ to _________.

                         Commission file number: 0-27596

                                 CONCEPTUS, INC.

             (Exact name of Registrant as specified in its charter)

                Delaware                                     94-3170244
    (State or other jurisdiction of                       (I.R.S. Employer
     incorporation or organization)                      Identification No.)

                               1021 Howard Avenue
                              San Carlos, CA 94070
                    (Address of principal executive offices)
       Registrant's telephone number, including area code: (650) 802-7240

                               -------------------


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for at least the past 90 days.

         Yes     X                                         No
               -----                                            -----

         As of June 30, 2000,  9,728,964 shares of the Registrant's Common Stock
were outstanding.

================================================================================


<PAGE>

<TABLE>

                                                CONCEPTUS, INC.

                                 FORM 10-Q For the Quarter Ended June 30, 2000

                                                     INDEX
<CAPTION>

                                                                                                                Page


<S>            <C>                                                                                              <C>


               Facing sheet                                                                                      1

               Index                                                                                             2

Part I.        Financial Information

Item 1.        a)     Consolidated balance sheets at June 30, 2000 and December 31, 1999                         3

               b)     Consolidated statements of operations for the three and six month periods ended June
                      30,  2000 and June 30, 1999                                                                4

               c)     Consolidated statements of cash flows for the six month periods ended June 30, 2000
                      and June 30, 1999                                                                          5

               d)     Notes to consolidated financial statements                                                 6

Item 2.        Management's Discussion and Analysis of Financial Condition and Results of Operations             7

Item 3.        Quantitative and Qualitative Disclosures About Market Risk                                        10

Part II.       Other Information                                                                                 11

               Signature                                                                                         12

               Index to Exhibits                                                                                 13




                                                          2
<PAGE>


                                                    PART I: FINANCIAL INFORMATION

ITEM 1.  Financial Statements


                                                           Conceptus, Inc.

                                                     Consolidated Balance Sheets
                                         (In thousands, except share and per share amounts)


                                                                                             June 30, 2000         December 31, 1999
                                                                                             -------------         -----------------
                                                                                               (Unaudited)               (Note 1)
<S>                                                                                                     <C>                <C>
Assets
       Current assets:
            Cash and cash equivalents                                                                      3,399              3,494
            Short-term investments                                                                         3,283              7,275
            Accounts receivable                                                                               18                 18
            Other current assets                                                                             307                 94
                                                                                                        --------           --------
       Total current assets                                                                                7,007             10,881

       Property and equipment, net                                                                           874                845
       Other assets                                                                                           54                177
                                                                                                        --------           --------
Total assets                                                                                            $  7,935           $ 11,903
                                                                                                        ========           ========


Liabilities and stockholders' equity
       Current liabilities:
            Accounts payable                                                                            $    468           $    130
            Clinical trial accruals                                                                          339                259
            Accrued compensation                                                                             500                235
            Other accrued liabilities                                                                        175                227
                                                                                                        --------           --------
       Total current liabilities                                                                           1,482                851

       Other long-term liabilities                                                                            89                138

       Commitments                                                                                          --                 --

       Stockholders' equity:
            Common stock, $0.003 par value, 30,000,000 shares authorized,                                 63,708             63,609
              9,728,964 and 9,661,731 shares issued and outstanding at
              June 30, 2000 and December 31, 1999, respectively
            Accumulated deficit                                                                          (57,344)           (52,695)
                                                                                                        --------           --------
       Total stockholders' equity                                                                          6,364             10,914
                                                                                                        --------           --------
                                                                                                        $  7,935           $ 11,903
                                                                                                        ========           ========


<FN>

                                                       See accompanying notes
</FN>
</TABLE>

                                                                 3

<PAGE>

<TABLE>


                                                           Conceptus, Inc.

                                                Consolidated Statements of Operations
                                                             (Unaudited)
                                              (In thousands, except per share amounts)

<CAPTION>

                                                                            Three Months Ended                  Six Months Ended
                                                                                 June 30,                           June 30,
                                                                      --------------------------          --------------------------
                                                                         2000              1999              2000              1999
                                                                         ----              ----              ----              ----
<S>                                                                   <C>               <C>               <C>               <C>
Net Sales                                                             $  --             $    38           $  --             $    68
Cost of Sales                                                            --                  44              --                  84
                                                                      -------           -------           -------           -------
Gross profit (loss)                                                      --                  (6)             --                 (16)

Operating expenses:
        Research and development                                        1,818             1,013             3,386             1,751
        Selling, general and administrative                             1,143               710             1,965             1,262
                                                                      -------           -------           -------           -------
Total operating expenses                                                2,961             1,723             5,351             3,013
                                                                      -------           -------           -------           -------

Operating loss                                                         (2,961)           (1,729)           (5,351)           (3,029)

Recovery of legal defense costs                                            60              --                 513              --
Interest and other income, net                                             11               230               189               448
                                                                      -------           -------           -------           -------
Net loss                                                              $(2,890)          $(1,499)          $(4,649)          $(2,581)
                                                                      =======           =======           =======           =======


Basic and diluted net loss per share                                  $ (0.30)          $ (0.16)          $ (0.48)          $ (0.27)
                                                                      =======           =======           =======           =======

Shares used in computing basic and diluted
   net loss per share                                                   9,692             9,626             9,686             9,623
                                                                      =======           =======           =======           =======



<FN>
                                                       See accompanying notes

</FN>
</TABLE>


                                                                 4
<PAGE>



                                 Conceptus, Inc.

                      Consolidated Statements of Cash Flows
                                   (Unaudited)
                                 (In thousands)


                                                             Six Months Ended
                                                                 June 30,
                                                          ----------------------
                                                            2000         1999
                                                          --------     --------
Cash flows used in operating activities
Net loss                                                  $ (4,649)    $ (2,581)
Adjustments to reconcile net loss to net
   cash used in operating activities:
   Depreciation and amortization                               249          331
   Amortization of deferred compensation                      --             47
   Changes in operating assets and liabilities
     Accounts receivable                                      --            118
     Other current assets                                     (213)        (155)
     Account payable                                           338           96
     Clinical trial accruals                                    80           --
     Accrued compensation                                      265         (230)
     Other accrued liabilities                                 (52)         (25)
     Other long-term liabilities                               (49)         (56)
                                                          --------     --------
Net cash used in operating activities                       (4,031)      (2,455)
                                                          --------     --------

Cash flows used in investing activities
   Maturities of investments                                 3,992        1,587
   Capital expenditures                                       (278)          (9)
   Change in other assets                                      123           48
                                                          --------     --------
Net cash provided by investing activities                    3,837        1,626
                                                          --------     --------

Cash flows provided by financing activities
   Proceeds from issuance of common stock                       99            3
                                                          --------     --------
Net cash provided by financing activities                       99            3
                                                          --------     --------

Net decrease in cash and cash equivalents                      (95)        (826)
Cash and cash equivalents at beginning of period             3,494       11,503
                                                          --------     --------
Cash and cash equivalents at end of period                $  3,399     $ 10,677
                                                          ========     ========


                             See accompanying notes

                                       5

<PAGE>

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

                                   (Unaudited)

Note 1.  Summary of Significant Accounting Policies

Method of Preparation

         The accompanying consolidated balance sheet as of June 30, 2000 and the
consolidated statements of operations and cash flows for the three and six month
periods  ended June 30,  2000 and 1999 have been  prepared  by  Conceptus,  Inc.
("Conceptus" or the "Company"), without audit. In the opinion of management, all
adjustments,  consisting  only of normal  recurring  adjustments,  necessary  to
present fairly the financial position,  results of operations, and cash flows at
June 30, 2000, and for all periods presented, have been made.

         Although  the  Company   believes   that  the   disclosures   in  these
consolidated financial statements are adequate to make the information presented
not  misleading,  certain  information  and  footnote  disclosures  required  by
Generally Accepted Accounting  Principles for complete financial statements have
been  omitted  pursuant  to the  rules and  regulations  of the  Securities  and
Exchange  Commission  ("SEC").  The balance  sheet at December 31, 1999 has been
derived from the audited financial  statements at that date. This financial data
should be reviewed in  conjunction  with the audited  financial  statements  and
notes thereto  included in the Company's  Form 10-K for the year ended  December
31, 1999.  The results of operations  for the six months ended June 30, 2000 may
not necessarily be indicative of the operating  results for the full 2000 fiscal
year.

Litigation Cost Recovery

         As of June 30, 2000, the Company  received an aggregate of $513,000 for
recovery of legal defense costs in connection with a sexual  harassment  lawsuit
filed against the Company in December 1997. The receipts were primarily from its
Directors' and Officers'  liability  insurance policy and were recorded as other
income.

Computation of Net Loss Per Share

         Basic net loss per share is computed using the weighted  average number
of common shares  outstanding  during the period.  Diluted net loss per share is
computed  using  the  weighted  average  number of common  and  dilutive  common
equivalent  shares  outstanding  during each period.  Under the requirements for
calculating  basic  net loss per  share,  the  effect  of  potentially  dilutive
securities  such as stock  options is  excluded.  Basic and diluted net loss per
share are  equivalent  for all periods  presented  due to the Company's net loss
position.

Comprehensive Income

         During the first six months of 2000 and 1999, total  comprehensive loss
approximates net loss as unrealized gains and losses were immaterial.

                                       6
<PAGE>

Item 2.  Management's Discussion and Analysis of Financial Condition and Results
of Operations

         The  following  discussion  should  be read  in  conjunction  with  the
unaudited  financial  statements and notes thereto  included in Part I-Item 1 of
this  Quarterly  Report.  In  addition,  except  for the  historical  statements
contained therein, the following discussion contains forward-looking  statements
within the meaning of Section 21E of the  Securities  Exchange  Act of 1934,  as
amended.  The Company wishes to alert readers that the risk factors set forth in
the Company's  Annual Report on Form 10-K for the year ended  December 31, 1999,
as well as other factors,  including those set forth in the following discussion
could in the future affect, and in the past have affected,  the Company's actual
results  and could  cause the  Company's  results  for future  periods to differ
materially from those expressed in any forward-looking  statements made by or on
behalf of the Company.

Overview

         Since  inception on September 18, 1992,  Conceptus  has been  primarily
engaged in the design,  development  and marketing of innovative  interventional
medical  devices for use in  reproductive  medicine.  The Company's  focus is to
develop the STOPTM non-surgical  permanent  contraception device for women. STOP
is designed to be a less-invasive, safer and less costly alternative to surgical
sterilization,  more commonly known as tubal ligation. 1994 data from the United
Nations estimate that 30% of worldwide  reproductive couples using contraception
rely on surgical  tubal  sterilization.  A survey  performed  by the Centers for
Disease  Control in 1995,  indicates  that surgical tubal  sterilization  is the
number one form of contraception in the United States,  and 35% of women aged 35
- 44 have had a surgical  tubal  sterilization.  An estimated  800,000  surgical
tubal  ligations are performed  annually in the U.S., of which 92% are performed
in a hospital or surgi-center and require general anesthesia.

         The Company's other products,  the ERA and FUTURA Resectoscope Sleeves,
the STARRT  Falloposcopy  system and the TTAC  products  have  produced  limited
revenues  since approval by the FDA and are not actively  marketed.  The Company
continues to consider various licensing and/or distribution strategies to market
these products,  but does not intend to expend significant  resources on further
product development or marketing activities on these products.

         The Company has a limited  history of  operations  and has  experienced
significant  operating losses since inception.  Operating losses are expected to
continue for at least the next several years as the Company  continues to expend
substantial  resources  to fund  clinical  trials in support of  regulatory  and
reimbursement approvals and to conduct research and product development.  Future
revenues and results of operations may fluctuate  significantly  from quarter to
quarter  and will depend  upon,  among  other  factors,  the extent to which the
Company's  products  gain market  acceptance,  the progress of clinical  trials,
actions relating to regulatory and  reimbursement  matters,  the introduction of
competitive  contraception  products,  the ability to attract marketing partners
and out-source manufacturing,  and the rate at which the Company establishes its
domestic and international distribution network.

Clinical Status

         In April,  2000,  Conceptus reported that it received approval from the
US Food & Drug  Administration  to  commence  the  pivotal  trial of the current
generation of the STOP device.  The pivotal trial  commenced in May,  2000,  and
will be conducted in 10-20  clinical sites in the U.S.,  Australia,  and Europe.
The  pre-market  portion  of the  pivotal  trial  will  include  400 women  with
bilateral  placement of the STOP device through  twelve months of  effectiveness
testing.  Conceptus  believes  that the  pre-market  portion of the trial may be
completed  in 2002 and FDA approval to market the STOP device in the U.S. may be
obtained in 2003.  Prior to FDA approval,  however,  the Company plans to market
STOP in certain  international  countries upon clearance from local governmental
bodies.

         The STOP  procedure  is designed to be a  non-surgical  alternative  to
tubal  sterilization  that can be performed in an office setting without general
anesthesia  and with minimal  recovery  time. As of February 4, 2000,  136 women
were  enrolled into the Phase II trial of the STOP device.  These  patients have
been  followed for varying  lengths of time and together have  accumulated  over
1,000 months of device wearing. Average procedure time was 20 minutes and device
placement was achieved in 90% of patients. In 93% of the cases, device placement
was  performed  without  the use of  general  anesthesia,  and  91% of  patients
reported  their  tolerance  to the  device  placement  procedure  as  "good"  to
"excellent".  Patient  tolerance to device  wearing after the placement has been
rated as "good" to "excellent"  in over 99% of patients in the follow-up  visits
completed  thus  far.  Adverse  events  occurred  in 6% of cases as a result  of
technical  failures or investigator  training  issues.  Conceptus  believes that
these types of events are typical of early stage clinical trials and may largely
be addressed through design evolution and physician training.

         Since the February 4, 2000 analysis,  patient enrollment into the Phase
II trial  continued,  and over 200 patients have been enrolled into the study to
date.  Approximately  140 of these women have  completed  the  required  3-month
alternative  contraception  period  and are  relying  on the  STOP  devices  for
contraception.  This represents about 900 woman months of effectiveness  testing
and no  pregnancies  have  been  reported  to the  Company  to date.  This  data
currently  supports a projected first year  effectiveness  rate of 96% and as is
true of all methods of birth control, STOP is not expected to be 100% effective.
The  Company  also notes that the data  gathered  in the  pivotal  trial will be
required to support a final  effectiveness rate for Pre-Market  Approval ("PMA")
submission.

         Separate from the Phase II studies  described  above, the STOP device's
theorized  mechanism of action was evaluated in  hysterectomy  patients who wore
the  devices  for  varying  lengths  of time prior to their  hysterectomy.  Data
obtained to date from the histological  analysis of the fallopian tubes in these
patients  supports  the  theorized  mechanism  of  action  of the  STOP  device.
Specifically,  the polyester fibers in the device elicit a local,  benign tissue
reaction which alters the function and architecture of the fallopian tube and is
occlusive  in  nature.  This  tissue  reaction  is  expected  to  result in both
long-term device retention and pregnancy prevention.

Clinical History of Discontinued Design

         From July 1997 through November 1998 an earlier  generation of the STOP
device  was  evaluated  in twenty  (20) women  separate  from the Phase II trial
discussed  above.  Device  placement was achieved in 14 of these 20 patients but
device expulsion occurred in four of the 14 patients. This unsatisfactory device
expulsion  rate  led  to the  discontinuation  of  this  design  and no  further
enrollment  into the trial. In June 2000, a pregnancy was reported in one of the
remaining ten women wearing the discontinued device. This woman's device was not
placed in  accordance  with the  clinical  protocol.  The FDA has not raised any
questions with respect to this pregnancy and the pregnancy

                                       7

<PAGE>


has had no effect on the FDA  approval  status of the pivotal  trial.  Since the
pivotal  trial to  support  the PMA of the STOP  device is based on the  current
generation design and does not involve the discontinued  design,  this pregnancy
will not be included in the calculation of the pivotal trial effectiveness rate.
As stated  above,  there  have  been no  reported  pregnancies  to date with the
current generation design.

                                       8

<PAGE>


Results of Operations - Three and Six Months Ended June 30, 2000 and 1999

         Sales  decreased  $38,000  and  $68,000  to zero for the  three and six
months  ended June 30, 2000 from the same  periods in the prior  year.  In 1998,
Conceptus ceased active  marketing and distribution of the TTAC,  STARRT and ERA
and FUTURA  products  and  focused on the STOP  product,  which  resulted in the
elimination  of revenue for the current year.  The Company  expects  revenues to
remain  immaterial  in 2000 as it continues to seek  regulatory  approval of the
STOP device in various countries.

         Cost of sales  decreased  $44,000 and $84,000 to zero for the three and
six months  ended June 30,  2000 from the same  periods in the prior  year.  The
decrease is due to the Company ceasing active  marketing and distribution of the
TTAC, STARRT and ERA and FUTURA products to focus solely on the STOP product.

         Research and development  ("R&D") expenses,  which include clinical and
regulatory expenses, increased 79% to $1,818,000 for the three months ended June
30,  2000,  from  $1,013,000  for the same period in the prior year.  In the six
months  ended  June 30,  2000 R&D  expenses  increased  93% to  $3,386,000  from
$1,751,000  for the same period in the prior year.  The  increases are primarily
due to the start of the company's  pivotal trial,  the continuation of its Phase
II trials, ongoing  pre-hysterectomy studies and scale up of the Company's pilot
manufacturing operations.

         Selling,  general and administrative ("SG&A") expenses increased 61% to
$1,143,000 for the three months ended June 30, 2000,  from $710,000 for the same
period in the prior year.  In the six months ended June 30, 2000,  SG&A expenses
increased 56% to  $1,965,000  from  $1,262,000  for the same period in the prior
year. The increases are primarily due to increased administrative costs required
to support growth in clinical and pilot manufacturing  activities.  In addition,
the Company  has  initiated a  marketing  function to perform  market  research,
develop  distribution  channels,  and  establish  reimbursement   strategies  in
preparation of a market introduction of STOP in certain international markets in
early 2001.

         As of June 30, 2000, the Company has received an aggregate of $513,000,
primarily from its Directors' and Officers'  insurance policy, for legal defense
costs reimbursement in connection with a sexual

                                       9

<PAGE>


harassment  lawsuit filed against the Company in December  1997. The receipt was
recorded as other income and the Company does not expect additional recovery.

         Net interest and other income decreased to $11,000 and $189,000 for the
three and six months  ended June 30,  2000,  from  $230,000 and $448,000 for the
same periods in the prior year.  The decreases are primarily the result of lower
average invested cash balances due to the usage of cash for operations. Interest
expense for the six months ended June 30, 2000 and 1999 were immaterial.

         The Company has a limited history of operations. Since its inception in
September  1992,  the  Company  has  been  engaged  primarily  in  research  and
development  of its T-TAC and STARRT  Falloposcopy  systems and its STOP device,
and since 1996, the ERA and FUTURA product lines. The Company has generated only
limited revenues and has only limited experience in manufacturing,  marketing or
selling  its  products in  commercial  quantities.  The Company has  experienced
significant  operating  losses since  inception and, as of June 30, 2000, had an
accumulated  deficit of $57.3 million.  The Company expects its operating losses
to  continue  for at least  the next  several  years as it  continues  to expend
substantial  resources in research and product  development and funding clinical
trials in support  of its STOP  device.  Due to the  expense  and  unpredictable
nature of these  activities,  there can be no  assurance  that the Company  will
achieve or sustain profitability in the future.

Liquidity and Capital Resources

         At June 30, 2000,  Conceptus had cash, cash equivalents and investments
of $6.7 million,  compared with $10.7 million at December 31, 1999. The decrease
is due to $4 million used in operating  and  investing  activities in support of
the STOP contraception product.

         Conceptus   believes  that  its  existing  capital  resources  will  be
sufficient  to  complete  enrollment  in the  STOP  pivotal  trial  but does not
currently have  sufficient  capital  resources to fund completion of the pivotal
trial nor the funds to successfully commercialize the STOP product. Accordingly,
the Company will require additional  financing and therefore,  may in the future
seek to raise additional funds through bank facilities, debt or equity offerings
or other sources of capital. Furthermore, any additional equity financing may be
dilutive  to  stockholders,  and  debt  financing,  if  available,  may  involve
restrictive  convenants.  Additional funding may not be available when needed or
on terms  acceptable to the Company,  which would have a material adverse effect
on the Company's business,  financial  condition and results of operations.  The
Company's  future liquidity and capital  requirements  will depend upon numerous
factors,  including the progress of the Company's  clinical research and product
development programs,  execution and implementation of partnering  arrangements,
the  receipt  of and the time  required  to  obtain  regulatory  clearances  and
approvals, and the resources devoted to developing,  manufacturing and marketing
the Company's products.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

The Company's cash balances in excess of short-term operating needs are invested
in highly liquid short-term  government  securities and high quality  commercial
paper. Due to the short-term and high quality nature of these  instruments,  the
Company  believes  these  financial  instruments  are  exposed to a low level of
interest rate risk.


                                       10
<PAGE>


Part II.  Other Information

Item 1.  Legal Proceedings

         There are no material pending or threatened legal  proceedings  against
the Company.  The Company from time to time is involved in routine legal matters
incident to its  business.  While  management  currently  believes the amount of
ultimate  liability,  if any, with respect to these actions will not  materially
affect the  financial  position,  results of  operations,  or  liquidity  of the
Company, the ultimate outcome of any litigation is uncertain.

Item 2.  Changes in Securities and Use of Proceeds

         None.

Item 3.  Defaults in Senior Securities

         None.

Item 4.  Submission of Matters to a Vote of Security Holders

<TABLE>
         The 2000 Annual Shareholders'  Meeting was held on May 25, 2000 and the
following votes were obtained, approving all matters proposed to stockholders:

<CAPTION>
          Proposal 1                   Required Vote         Votes For Nominee         Votes Withheld
          ----------                   -------------         -----------------         --------------
<S>                               <C>                               <C>                      <C>
    Nomination of Directors       Plurality of votes cast.
-        Howard Palefsky                                            8,935,124                121,068
-        Kathryn Tunstall                                           8,940,692                115,500
-        Sanford Fitch                                              8,940,644                115,548
-        Florence Comite                                            8,940,692                115,500

    Directors Steve Bacich and Rick Randall continue in office until 2001.

          Proposal 2                   Required Vote                   For                   Against          Abstain
          ----------                   -------------                   ---                   -------          -------
 Appointment of Ernst & Young        Majority of votes              9,035,573                 9,109            11,510
     Independent Auditors                  cast

          Proposal 3                   Required Vote                   For                   Against          Abstain
          ----------                   -------------                   ---                   -------          -------
  Increase in 500,000 shares         Majority of votes              4,929,109                353,492           10,840
  reserved for issuance under              cast
      the 1993 Stock Plan
</TABLE>


Item 5.  Other Information

         None.

Item 6.  Exhibits and Reports on Form 8-K

         (a) Exhibits:

             10.31       Fourth   Addendum   to  Lease   Agreement   with   Dani
                         Investments Partners.

             27          Financial Data Schedule

         (b) Reports on Form 8-K.

                  None.




                                       11
<PAGE>


SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  Registrant  has duly  caused  this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                CONCEPTUS, INC.

                                    By: /s/            OLIVER BROUSE
                                        ----------------------------------------
                                                       Oliver Brouse
                                               Principal Accounting Officer

Date:    July 18, 2000


                                       12
<PAGE>


                                INDEX TO EXHIBITS

      Exhibit
       Number                             Description
       ------                             -----------
         10.32                  Fourth Addendum to Lease Agreement with
                                Dani Investment Partners

         27                     Financial Data Schedule




                                       13